What does “Repatha LOE” mean?
“Repatha” is the brand name for evolocumab, a PCSK9 inhibitor. “LOE” most often means “loss of exclusivity”—the point when a drug’s market exclusivity ends and generic or biosimilar competition may be able to enter, depending on the specific legal and regulatory situation.
When is Repatha’s loss of exclusivity (LOE)?
DrugPatentWatch tracks Repatha’s exclusivity and patent timelines and flags potential dates tied to loss of exclusivity. You can check the most up-to-date LOE-related information here: DrugPatentWatch – Repatha (evolocumab).
How is LOE different from patent expiry?
LOE is about when exclusivity protection ends, which can be driven by regulatory exclusivity periods and other protections. Patent expiry is about when specific patents end. They can align, but they don’t always match—later patent litigation can also delay entry even after earlier exclusivity ends (or vice versa).
Why do people search “Repatha LOE” in particular?
Users often want LOE dates to estimate:
- when biosimilar/generic-like competition could start,
- likely price pressure and pharmacy formulary changes,
- whether insurers may shift coverage.
Because those outcomes depend on the exact legal status, the best source is a live patent/exclusivity tracker like DrugPatentWatch.
If you meant something else by “loe”
“LOE” can also be used in other contexts (for example, “level of effort” in project settings). If you tell me what context you saw “Repatha loe” in—pricing, patents, coverage, or a specific document—I can interpret it more precisely.